Osteopontin Promotes Expression of Matrix Metalloproteinase 13 through NF-κB Signaling in Osteoarthritis

Figure 1

OPN promotes expression of MMP13. ((a)-(b)) The expression of OPN ((a), ) and MMP13 ((b), ) in normal cartilage tissues obtained from non-OA patients and degenerated cartilage tissues from OA patients. ((c)–(e)) OPN treatment at indicated concentrations promotes expression of MMP13 at mRNA (c) and protein levels ((d) and (e)) in the chondrocytes. (d) Immunoblotting of MMP13. (e) Quantification of relative MMP13 abundance from data shown in (d). ((f)–(h)) OPN treatment at indicated time promotes expression of MMP13 at mRNA (f) and protein levels ((g) and (h)) in the chondrocytes. (g) Immunoblotting of MMP13. (h) Quantification of relative MMP13 abundance from data shown in (g). Data are representative of two independent experiments with 4–6 repeats per group. indicates a statistically significant difference between two groups (). OA: osteoarthritis; OPN: osteopontin; and MMP13: matrix metalloproteinase 13.

(a)

(b)

(c)

(d)

(e)

(f)

(g)

(h)